Page last updated: 2024-12-10

robinetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

robinetin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

robinetin : A pentahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 7, 3, 4' and 5'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281692
CHEMBL ID170405
CHEBI ID8876
SCHEMBL ID217743
MeSH IDM0119383

Synonyms (53)

Synonym
3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-chromen-4-one
3,7-dihydroxy-2-(3,4,5-trihydroxy-phenyl)-chromen-4-one
bdbm50033767
3,3'',4'',5'',7-pentahydroxy flavone
3,7,3'',4'',5''-pentahydroxyflavone
nsc-656274
flavone, 3,3',4',5',7-pentahydroxy-
brn 0308905
3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4-benzopyrone
nsc 407331
ccris 7520
3,3',4',5',7-pentahydroxyflavone
norkanugin
nsc 656274
einecs 207-709-6
flavone,3',4',5',7-pentahydroxy-
nsc407331
wln: t66 bo evj cr cq dq eq& dq iq
nsc-407331
5-deoxymyricetin
490-31-3
robinetin
3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one
4h-1-benzopyran-4-one, 3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-
nsc656274
NCGC00163615-01
3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-4h-1-benzopyran-4-one
chebi:8876 ,
CHEMBL170405 ,
LMPK12111577
AKOS016009494
3,7,3',4',5'-pentahydroxuflavone
kj6dbc4u7e ,
5-hydroxyfisetin
unii-kj6dbc4u7e
5-18-05-00562 (beilstein handbook reference)
SCHEMBL217743
CCG-208323
4h-1-benzopyran-4-one, 3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)
3,7,3',4',5'-pentahydroxyflavone
mfcd00016783
SOEDEYVDCDYMMH-UHFFFAOYSA-N
DTXSID30197654
sr-05000002311
SR-05000002311-2
FT-0724738
Q27108166
bis[3,5-bis(trifluoromethyl)phenyl]-phosphine oxide
A871845
AS-81054
CS-0016755
HY-N1347
E87017

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The implementation of this assay to the screening of a highly diverse academic chemical library of 14,300 molecules yielded, after secondary assays and generation of dose-response curves, the identification of two natural product inhibitors, cyanidin and delphinidin."( Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
Haiech, J; Hibert, M; Kellenberger, E; Kuhn, I; Lobstein, A; Muller-Steffner, H; Rognan, D; Said-Hassane, F; Schuber, F; Villa, P, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pentahydroxyflavoneA hydroxyflavone substituted by five hydroxy groups.
7-hydroxyflavonolAny flavonol carrying a 7-hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.28180.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.28180.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency11.19360.140911.194039.8107AID2451
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency4.46680.125919.1169125.8920AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID485281
phosphopantetheinyl transferaseBacillus subtilisPotency1.12200.141337.9142100.0000AID1490
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.23780.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)IC50 (µMol)37.90006.00006.83338.2000AID603318
Multidrug resistance-associated protein 1 Homo sapiens (human)Ki5.00000.07002.20208.1000AID427747
Xanthine dehydrogenase/oxidaseBos taurus (cattle)IC50 (µMol)4.30000.00303.10159.8000AID338975
Integrase Human immunodeficiency virus 1IC50 (µMol)3.75000.00051.544310.0000AID93507; AID93508
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
response to hypoxiaADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
signal transductionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
female pregnancyADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to xenobiotic stimulusADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
negative regulation of neuron projection developmentADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
artery smooth muscle contractionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
NAD metabolic processADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of cell growthADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of B cell proliferationADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of insulin secretionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to estradiolADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to retinoic acidADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to progesteroneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to hydroperoxideADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
B cell proliferationADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
negative regulation of apoptotic processADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
negative regulation of bone resorptionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
B cell receptor signaling pathwayADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
long-term synaptic depressionADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
response to interleukin-1ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
apoptotic signaling pathwayADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
leukotriene metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
response to xenobiotic stimulusMultidrug resistance-associated protein 1 Homo sapiens (human)
cobalamin transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid biosynthetic processMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to oxidative stressMultidrug resistance-associated protein 1 Homo sapiens (human)
heme catabolic processMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transportMultidrug resistance-associated protein 1 Homo sapiens (human)
phospholipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
positive regulation of inflammatory responseMultidrug resistance-associated protein 1 Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cell chemotaxisMultidrug resistance-associated protein 1 Homo sapiens (human)
transepithelial transportMultidrug resistance-associated protein 1 Homo sapiens (human)
cyclic nucleotide transportMultidrug resistance-associated protein 1 Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 1 Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid translocationMultidrug resistance-associated protein 1 Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
cellular response to amyloid-betaMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 1 Homo sapiens (human)
xanthine catabolic processXanthine dehydrogenase/oxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
NAD+ nucleosidase activityADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
transferase activityADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
identical protein bindingADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
NAD+ nucleotidase, cyclic ADP-ribose generatingADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
phosphorus-oxygen lyase activityADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type vitamin B12 transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
sphingolipid transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
carboxylic acid transmembrane transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 1 Homo sapiens (human)
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine oxidase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
iron ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdenum ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
protein homodimerization activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
FAD bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
plasma membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
cell surfaceADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
basolateral plasma membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
nuclear membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
extracellular exosomeADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
plasma membraneADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basal plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
lateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular exosomeMultidrug resistance-associated protein 1 Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 1 Homo sapiens (human)
extracellular spaceXanthine dehydrogenase/oxidaseBos taurus (cattle)
peroxisomeXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine dehydrogenase complexXanthine dehydrogenase/oxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1631854Antiparasitic activity against Leishmania infantum MOM/MA67ITMAP263 amastigotes infected in human THP1 cells at 10 uM after 72 hrs by steady-glo luminescence assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1631837Inhibition of Trypanosoma brucei PTR1 at 50 uM using H2B as substrate incubated for 10 mins followed by addition of NADPH measured for 10 to 50 mins2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID671213Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID671219Inhibition of prostate specific antigen expression in human 22Rv1 cells assessed as PSA protein level at 10 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID456187Inhibition of reduced carboxymethylated kappa-casein fibril formation measured every 5 mins after 1000 mins by thioflavin T staining-based binding assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
AID338975Inhibition of cow milk xanthine oxidase
AID1631857Cytotoxicity against human THP1 cells after 72 hrs by MTT assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID310882Inhibition of HIV1 replication2007Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
Simple criterion for selection of flavonoid compounds with anti-HIV activity.
AID671218Inhibition of androgen receptor expression in human 22Rv1 cells assessed as AR protein level at 20 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1631834Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms after 72 hrs by resazurin-based assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1631847Inhibition of recombinant full-length human aurora B kinase expressed in baculovirus system using MBP as substrate at 10 uM incubated for 45 mins by ADP-glo kinase assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1631844Mitochondrial toxicity in human 786-O cells incubated for 6 hrs by mitotracker red staining based-uptake method2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID404008Cytotoxicity against human KB cells
AID671217Inhibition of androgen receptor expression in human 22Rv1 cells assessed as AR protein level at 10 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1334869Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-activity relationship of the inhibitory effects of flavonoids on nitric oxide production in RAW264.7 cells.
AID1631858Selectivity index, ratio of CC50 for human THP1 cells to EC50 for Trypanosoma brucei brucei Lister 427 bloodstream forms2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID502292Antioxidant activity assessed as DDPH radical scavenging activity2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Relationships between structures of hydroxyflavones and their antioxidative effects.
AID93507IC50 was measured as concentration required to inhibit 50% of HIV-integrase cleavage1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study.
AID338974Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID537627Inhibition of Schistosoma mansoni recombinant NAD+ glycohydrolase expressed in Pichia pastoris by continuous fluorometric method2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
AID427747Inhibition of MRP1 transfected in MDCK2 cells assessed as inhibition of calcein transport2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
AID1631840Inhibition of Trypanosoma brucei DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID93508IC50 was measured as concentration required to inhibit 50% of HIV-integrase integration1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study.
AID456191Inhibition of reduced carboxymethylated kappa-casein fibril formation assessed as formation of shorter and stunted fibrils at 1 uM by transmission electron microscopy2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
AID671220Inhibition of prostate specific antigen expression in human 22Rv1 cells assessed as PSA protein level at 20 uM after 72 hrs by densitometry relative to untreated control2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and biological evaluation of novel flavonols as potential anti-prostate cancer agents.
AID1631846Cytotoxicity against human WI38 cells at 100 uM after 48 hrs by cell titer glo assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID400607Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression at 10 uM after 18 hrs measured as microunits of tissue factor/10'5 cells1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID456186Inhibition of reduced carboxymethylated kappa-casein fibril formation at 5 ug/mL measured every 5 mins after 1000 mins by thioflavin T staining-based binding assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
AID1631845Cytotoxicity against human A549 cells at 100 uM after 48 hrs by cell titer glo assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1631839Inhibition of Leishmania mexicana DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID336952Inhibition of bovine thymocytes protein tyrosine kinase assessed as angiotensin 1 phosphorylation
AID603318Inhibition of human CD38 using 20 uM 1, N6-etheno NAD+ as substrate by continuous fluorimetric method2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
Flavonoids as inhibitors of human CD38.
AID1631842Inhibition of human thymidylate synthase at 50 uM using folic aid as substrate by spectrophotometric analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1631841Inhibition of human DHFR at 50 uM using folic aid as substrate by spectrophotometric analysis2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (13.04)18.7374
1990's3 (13.04)18.2507
2000's4 (17.39)29.6817
2010's11 (47.83)24.3611
2020's2 (8.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.83 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]